Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

Ilaria Galgani; Airi Poder; Rain Jogi; Veli-Jukka Anttila; Stefano Milleri; Alberto M. Borobia; Odile Launay; Marco Testa; Daniela Casula; Luca Grassano; Annaelisa Tasciotti; Marie Dozot; Ashwani K. Arora

doi:10.1080/21645515.2023.2187194

Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

Ilaria Galgani, Airi Poder, Rain Jogi, Veli-Jukka Anttila, Stefano Milleri, Alberto M. Borobia, Odile Launay, Marco Testa, Daniela Casula, Luca Grassano, Annaelisa Tasciotti, Marie Dozot, Ashwani K. Arora

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Artikelnummer	2187194
Tidskrift	Human Vaccines & Immunotherapeutics
Volym	19
Nummer	1
Antal sidor	10
ISSN	2164-5515
DOI	https://doi.org/10.1080/21645515.2023.2187194
Status	Publicerad - 31 dec. 2023
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

318 Medicinsk bioteknologi
11832 Mikrobiologi och virologi

Åtkomst av dokument

10.1080/21645515.2023.2187194

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-McatSlutlig publicerad version, 4,03 MBLicens: CC BY-NC-ND

Citera det här

Galgani, I., Poder, A., Jogi, R., Anttila, V.-J., Milleri, S., Borobia, A. M., Launay, O., Testa, M., Casula, D., Grassano, L., Tasciotti, A., Dozot, M., & Arora, A. K. (2023). Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial. Human Vaccines & Immunotherapeutics, 19(1), Artikel 2187194. https://doi.org/10.1080/21645515.2023.2187194

@article{a2e71e16515e4c1d84bb9a0b34d0dde1,

title = "Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial",

keywords = "As01, Moraxella catarrhalis, Adjuvant system, Chronic obstructive pulmonary disease, Immune response, Non-inferiority, non-typable Haemophilus influenzae, Recombinant zoster vaccine, 318 Medical biotechnology, 11832 Microbiology and virology",

author = "Ilaria Galgani and Airi Poder and Rain Jogi and Veli-Jukka Anttila and Stefano Milleri and Borobia, {Alberto M.} and Odile Launay and Marco Testa and Daniela Casula and Luca Grassano and Annaelisa Tasciotti and Marie Dozot and Arora, {Ashwani K.}",

year = "2023",

month = dec,

day = "31",

doi = "10.1080/21645515.2023.2187194",

language = "English",

volume = "19",

journal = "Human Vaccines & Immunotherapeutics",

issn = "2164-5515",

publisher = "TAYLOR & FRANCIS INC",

number = "1",

}

Galgani, I, Poder, A, Jogi, R, Anttila, V-J, Milleri, S, Borobia, AM, Launay, O, Testa, M, Casula, D, Grassano, L, Tasciotti, A, Dozot, M & Arora, AK 2023, 'Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial', Human Vaccines & Immunotherapeutics, vol. 19, nr. 1, 2187194. https://doi.org/10.1080/21645515.2023.2187194

Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial. / Galgani, Ilaria; Poder, Airi; Jogi, Rain et al.
I: Human Vaccines & Immunotherapeutics, Vol. 19, Nr. 1, 2187194, 31.12.2023.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

TY - JOUR

T1 - Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone

T2 - Results from a randomized, phase 2a, non-inferiority trial

AU - Galgani, Ilaria

AU - Poder, Airi

AU - Jogi, Rain

AU - Anttila, Veli-Jukka

AU - Milleri, Stefano

AU - Borobia, Alberto M.

AU - Launay, Odile

AU - Testa, Marco

AU - Casula, Daniela

AU - Grassano, Luca

AU - Tasciotti, Annaelisa

AU - Dozot, Marie

AU - Arora, Ashwani K.

PY - 2023/12/31

Y1 - 2023/12/31

KW - As01

KW - Moraxella catarrhalis

KW - Adjuvant system

KW - Chronic obstructive pulmonary disease

KW - Immune response

KW - Non-inferiority

KW - non-typable Haemophilus influenzae

KW - Recombinant zoster vaccine

KW - 318 Medical biotechnology

KW - 11832 Microbiology and virology

U2 - 10.1080/21645515.2023.2187194

DO - 10.1080/21645515.2023.2187194

M3 - Article

C2 - 36974988

SN - 2164-5515

VL - 19

JO - Human Vaccines & Immunotherapeutics

JF - Human Vaccines & Immunotherapeutics

IS - 1

M1 - 2187194

ER -

Galgani I, Poder A, Jogi R, Anttila VJ, Milleri S, Borobia AM et al. Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial. Human Vaccines & Immunotherapeutics. 2023 dec. 31;19(1):2187194. doi: 10.1080/21645515.2023.2187194